RxDoctor Payments DataLook up a doctor →

Amit Verma, MD

Internal Medicine · Dallas, TXNPI 1033299524

Payments from drug & device makers

$7,726,065in general payments, 2019–2025

Across 177 payments — averaging $43,650 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novartis$6.1M
  • Janssen Research & Development, LLC$1.2M
  • Bristol Myers Squibb$156K
  • Pfizer$100K
  • Otsuka Pharmaceutical Co., Ltd.$59K
  • Takeda Pharmaceuticals U.S.A., Inc.$36K
  • plus $130K from 15 others
$17,015in research payments, 2019–2025

Across 8 payments — averaging $2126.88 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Bristol Myers Squibb$10K
  • Pfizer$7K

What the payments were for

  • Consulting fees$46,01387%
  • Speaking & faculty fees$1,2702%
  • Travel & lodging$5671%
  • Food & beverage$4501%
  • Education$4,6719%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$7,726,065 in reported general payments places this provider in the 95th percentile of 7,675 internal medicine providers in Texas.

See all internal medicine providers in Texas

Medicare billing

Part B allowed, 2024
$13,292
Medicare patients
39
Services billed
878

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other internal medicine in Dallas

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →